Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced...
Barchart Research What to Expect from NVCR Earnings NVCR Generated April 29, 2026 Current Price $11.93 EPS Estimate $$-0.40 Consensus Rating Moderate Buy Average Move 8.34% NovoCure's Narrowing Losses...
Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...
Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ® ), ...
Novocure to launch Optune Lua in Japan with national reimbursement coverage
Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann,...
Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax ® approved by the U.S. FDA for the...
British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients